Surveyor Capital
Biotech Investor · 4 portfolio companies
Portfolio
4
Combined Value
$3.5B
Focus Areas
6
Top Stage
Phase 1/2
Portfolio Companies
| Company | Valuation |
|---|---|
| Dyne Therapeutics | $3.0B |
| Contineum Therapeutics | $524.2M |
| ProfoundBio | — |
| Acelyrin | — |
Biotech Investor · 4 portfolio companies
| Company | Valuation |
|---|---|
| Dyne Therapeutics | $3.0B |
| Contineum Therapeutics | $524.2M |
| ProfoundBio | — |
| Acelyrin | — |